Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis

被引:90
作者
Höxtermann, S [1 ]
Nüchel, C [1 ]
Altmeyer, P [1 ]
机构
[1] Ruhr Univ Bochum, Dept Dermatol, D-44791 Bochum, Germany
关键词
psoriasis; fumaric acid ester; cell count reduction; CD4(+); CD8(+); T cells;
D O I
10.1159/000017903
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: For severe forms of psoriasis vulgaris, the antipsoriatic fumaric acid esters (FAE) therapy has recently gained increasing acceptance and importance. Until today, there is little knowledge about the mode of action of FAE. However, some evidence exists indicating immunosuppressive effects. Objective: The aim of this study was to examine the systemic, particularly the immunological changes in patients suffering from psoriasis treated with FAE over a long period of time, since we expect to see pharmacological effects of FAE at this point. Methods: This study is based on continuously recorded clinical data and laboratory parameters of 10 patients, who were treated over a period of 12 months with FAE. A quantitative analysis of lymphocytes and their subtypes was carried out by means of flowcytometric methods. Results: 3 months after starting treatment with FAE, a clinical effect with a remission index >95% was achieved in all 10 patients examined. This remained constant until the end of this study. Focusing on leukopenia, and particulary on lymphopenia as important parameters, these effects were found in all patients. The lymphocyte subpopulations data demonstrated extensive proportionate reductions. Within the T cell fraction a stronger suppression of CD8(+) lymphocytes was observed. Conclusion: Our investigations of systemic effects of fumaric acid esters demonstrate the suppressive character of this medication, Effects of cell count reduction in leukocyte and lymphocyte numbers over the entire period of 12 months could be observed. The lymphocytic cell count number is obviously linked to the clinical effect.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 21 条
[1]  
Altmeyer P, 1996, ANN DERMATOL VENER, V123, P838
[2]   Efficacy and safety profile of fumaric acid esters in oral long-term therapy of severe psoriasis vulgaris. An investigation of 83 patients [J].
Altmeyer, P ;
Hartwig, R ;
Matthes, U .
HAUTARZT, 1996, 47 (03) :190-196
[3]  
ALTMEYER P, 1996, DT ARZTEBLATT, V48, pA3194
[4]   ANTIPSORIATIC EFFECT OF FUMARIC-ACID DERIVATIVES - RESULTS OF A MULTICENTER DOUBLE-BLIND-STUDY IN 100 PATIENTS [J].
ALTMEYER, PJ ;
MATTHES, U ;
PAWLAK, F ;
HOFFMANN, K ;
FROSCH, PJ ;
RUPPERT, P ;
WASSILEW, SW ;
HORN, T ;
KREYSEL, HW ;
LUTZ, G ;
BARTH, J ;
RIETZSCHEL, I ;
JOSHI, RK .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 30 (06) :977-981
[5]  
[Anonymous], AKTUEL DERMATOL
[6]  
BACHARACHBUHLES M, 1994, ACTA DERM-VENEREOL, V74, P79
[7]   T-CELL SUBPOPULATIONS IN THE BLOOD AND SKIN OF PATIENTS WITH PSORIASIS [J].
BAKER, BS ;
SWAIN, AF ;
VALDIMARSSON, H ;
FRY, L .
BRITISH JOURNAL OF DERMATOLOGY, 1984, 110 (01) :37-44
[8]  
BAYARD W, 1987, HAUTARZT, V110, P37
[9]  
Kemeny L, 1994, Exp Dermatol, V3, P1, DOI 10.1111/j.1600-0625.1994.tb00259.x
[10]  
MATTHES U, 1995, AKTUEL DERMATOL, V21, P40